.

Vital Therapies reported 106K in Interest Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Income Change
BioMarin Pharmaceutical BMRN:US 2.5M 685K
Dynavax Technologies DVAX:US 765K 504K
Regulus Therapeutics RGLS:US 79K 73K
Revance Therapeutics RVNC:US 619K 543K
Ultragenyx Pharmaceutical RARE:US 899K 405K
United Therapeutics UTHR:US 6.8M 2.5M
Vital Therapies VTL:US 106K 99K